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Preliminary clinical data indicate that omega-3 fatty acids may be effective mood stabilizers for patients with bipolar disorder. Both lithium and valproic acid are known to inhibit protein kinase C (PKC) activity after subchronic administration in cell culture and in vivo. The current study was undertaken to determine the effects of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on protein kinase C phosphotransferase activity in vitro. Various concentrations of DHA, EPA, and arachidonic acid (AA) were incubated with the catalytic domain of protein kinase C beta from rat brain. Protein kinase C activity was measured by quantifying incorporation of 32 P-PO 4 into a synthetic peptide substrate. Both DHA and EPA, as well as the combination of DHA and EPA, inhibited PKC activity at concentrations as low as 10 mol l −1 . In contrast, arachidonic acid had no effect on PKC activity. Thus, PKC represents a potential site of action of omega-3 fatty acids in their effects on the treatment of bipolar disorder. Molecular Psychiatry (2001) 6, 246-248.
Accumulating evidence from several laboratories suggests that lithium and valproate, the primary treatments for bipolar disorder, exert inhibitory actions at various sites along the second-messenger cascade, which may account for the mood-stabilizing effects of these medications. In particular, both affect protein kinase C (PKC) activity. [1] [2] [3] [4] [5] [6] [7] Preliminary evidence suggests that omega-3 fatty acids may also affect PKC. 8, 9 A clinical pilot study, undertaken based on this putative mechanistic commonality, concluded that omega-3 fatty acids may be effective mood stabilizers for patients with bipolar disorder. In a recent 4-month, double-blind, placebo-controlled study, outpatients who received omega-3 fatty acids in addition to stable doses of their baseline medications had a significantly longer period of remaining well than the placebo group, and performed better for nearly every other outcome measure. 10 Further data regarding omega-3 fatty acids are particularly crucial because these compounds exhibit several properties that make them attractive potential therapeutic modalities, including a highly favorable safety profile and lack of teratogenicity. The current study was undertaken to characterize the effects and potency of the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaneoic acid (EPA) on PKC activity in vitro, using the catalytic domain of protein kinase C beta from rat brain. Both DHA and EPA, as well as the combination of DHA and EPA, inhibited PKC activity at concentrations as low as 10 mol l . Figure 1 shows that EPA significantly inhibited the activity of the catalytic domain of PKC at concentrations of 10 M and higher, with an estimated IC 50 of 7 M. EPA displayed little inhibition of enzyme activity at concentrations less than or equal to 1 M. Similarly, the omega-3 fatty acid DHA significantly inhibited enzyme activity at low concentrations, with an estimated IC 50 of 3 M (Figure 2 ). Again, enzyme activity was essentially completely inhibited at DHA concentrations of 10 M and higher. The combination of EPA and DHA, in a 2:1 ratio similar to that found in fish oil used in the previous clinical trial, 10 produced similar inhibition of PKC activity at comparable concentrations of EPA and DHA alone (IC 50 of 7 M EPA/3.5 M DHA). AA, a saturated omega-6 fatty acid, was included in this study as a negative control for the Figure 1 Effect of EPA on PKC activity. The omega-3 fatty acid EPA significantly inhibited the activity of the catalytic domain of PKC at concentrations of 10 M and higher, with an estimated IC 50 of 7 M. EPA displayed little inhibition of enzyme activity at concentrations less than or equal to 1 M. Thus, EPA is an effective and surprisingly potent inhibitor of PKC activity. The uninhibited (100%) specific activity of PKC employed in the assays was 234 117 pmol min
Figure 2
Effect of DHA on PKC activity. The omega-3 fatty acid DHA significantly inhibited enzyme activity at low concentrations, with an estimated IC 50 of 3 M. Enzyme activity was essentially completely inhibited at DHA concentrations of 10 M and higher. The uninhibited (100%) specific activity of PKC employed in the assays was 234 117 pmol min
nonspecific effects of lipids on the phosphotransferase activity of the catalytic domain of PKC. As predicted, AA did not produce significant inhibition of enzyme activity at any concentration assayed. Data for AA are not provided in this report. In summary, DHA and EPA, as well as the combination of DHA and EPA in a 2:1 ratio similar to that of fish oil, produced strong inhibition of the catalytic domain of PKC, at concentrations much lower than previously reported in studies with the holoenzyme of PKC. This effect does not appear to be universal to fatty acids, since the omega-6 fatty acid (AA) did not inhibit PKC. Omega-3 fatty acids (EPA and DHA) have been reported to inhibit fully-activated PKC (PKC activated by phosphatidylserine and/or diolein) at high concentrations (100-800 M).
9 However, studies with PKC and mood stabilizing medications undertaken with the holoenzyme of PKC are complicated by the fact that it is necessary to add lipid activators of PKC to stimulate the enzyme. Lipid-containing micelles under these conditions may greatly diminish the effective concentration of EPA and DHA in the assays, resulting in an underestimate of the potencies of the compounds for inhibiting PKC. In addition, EPA and DHA might have nonspecific or indirect effects on PKC activation under these conditions by altering the availability or local concentrations of the lipophilic cofactors phosphatidyl serine (PS) and diacylglycerol (DAG).
To eliminate these complications, we undertook the present studies using the purified, isolated catalytic subunit of PKC from rat brain, which is active in the absence of any added cofactors. The use of this preparation allowed us to test the hypothesis that omega-3 fatty acids DHA and EPA have direct inhibitory effects on the catalytic domain of the beta isozyme of PKC. By eliminating the need for lipid activators in our assays with the enzyme catalytic domain, we have shown that DHA and EPA inhibit PKC activity at much lower concentrations than expected. This disparity may be Molecular Psychiatry explained by interactions between omega-3 fatty acids and lipophilic cofactors, which create micelles in in vitro studies, resulting in either diminished effective concentrations of EPA and DHA, or decreased availability of holoenzyme activators.
The mood stabilizing role of omega-3 fatty acids is being investigated in several current studies. If proven effective, these compounds have the benefits of high patient acceptance, relatively few side effects, no documented adverse drug interactions, and apparent safety in pregnancy and children. 11 In the absence of a known effective dose, clinical studies to date have used high doses (9.6 g day −1 ) to minimize the likelihood of a false negative finding due to under-dosing. 10 Both lithium and valproate decrease the activity of cellular PKC at concentrations that are similar to the known therapeutic concentrations in humans. 12 If the in vitro data for omega-3 fatty acids predict the relevant therapeutic concentration in humans, lower doses of omega-3 fatty acids may be appropriate for future clinical studies.
Furthermore, there has been controversy about which component of fish oils is most psychiatrically relevant. DHA occurs in higher concentrations in the brain, and is essential for the development of the neonatal brain. On the other hand, EPA is more relevant to the cytokine theories of depression. Our data indicate that both EPA and DHA alone may be potent and effective, if indeed PKC inhibition is mechanistically important to mood stabilizing effects.
Our results support the hypothesis that omega-3 fatty acids may suppress aberrant signal transduction in the pathogenesis of bipolar disorder. Further studies with the PKC holoenzyme are needed to evaluate the effects of omega-3 fatty acids on the activity and distribution of isozymes of PKC in vitro, as well as cellular PKC, before more definite conclusions are made about the mechanism of action of omega-3 fatty acids on PKC in vivo. We plan to expand our studies to determine if omega-3 fatty acids might also have similar inhibitory effects on other regulators of cellular signal transduction pathways with structural homology to PKC, including protein kinase A (PKA) and mitogen-activated protein kinases (map kinases), as well as other regulators of gene expression, such as the neuroprotective and neurotrophic protein bcl-2, that have been shown to be modulated by known mood stabilizers.
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Materials and methods
Materials
The catalytic subunit of protein kinase C from rat brain was obtained from Calbiochem-Novabiochem Corporation (La Jolla, CA, USA). Gamma-32 P-ATP was obtained from Amersham Pharmacia Biotech (Piscataway, NJ, USA). All other reagents were obtained from Sigma Chemical Company (St Louis, MO, USA): sodium salt of docosahexaenoic acid (22:6n-3), sodium salt of eicosapentaenoic acid (20:5n-3), and sodium salt of arachidonic acid (AA) (20:4n-6), an omega-6 fatty acid.
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Protein kinase C determination Various concentrations of DHA, EPA, and AA were incubated with the catalytic domain of protein kinase C beta from rat brain. Concentrations of DHA, EPA, and AA ranged from 0.1 M to 400 M, based on concentrations used in prior in vitro studies with omega-3 fatty acids. 8, 9, 16 Enzyme activity was measured by quantifying incorporation of 32 P-PO 4 into a synthetic peptide substrate. 17 The reaction mixture consisted of 20 ng of the catalytic subunit of PKC, 20 mM Tris-HCl (pH 7.5), 0.5 mM EGTA, 1 mM EDTA, 2 mM Na 2 PO 4 , deionized H 2 O, 20 M protein substrate, 1 mM ATP, 1 Ci ml −1 gamma-32 P-ATP, 10 mM MgCl 2 . After 20 min of incubation at 37°C, the reaction was stopped by addition of 225 mM H 3 PO 4 and 1 mM ATP. Phosphorylated proteins were transferred to filter paper, and then the filter paper was washed three times in 150 mM H 3 PO 4 and once in ethanol. Enzyme activity was quantified as the amount of 32 P incorporation on to a peptide substrate measured by liquid scintillation spectroscopy.
Concentrations of omega-3 (DHA and EPA) and omega-6 (AA) fatty acids, are specified in the appropriate figures. Each enzyme reaction was assayed in duplicate and repeated three times, and each figure denotes the mean plus or minus the standard error of these determinations.
